Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis.
about
Antithrombin III for critically ill patientsTreatment for disseminated intravascular coagulation in patients with acute and chronic leukemiaAntithrombin III for critically ill patientsSepsis and disseminated intravascular coagulationCombination effect of antithrombin and recombinant human soluble thrombomodulin in a lipopolysaccharide induced rat sepsis modelA randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsisEfficacy of antithrombin in preclinical and clinical applications for sepsis-associated disseminated intravascular coagulation.Four-day antithrombin therapy does not seem to attenuate hypercoagulability in patients suffering from sepsis.Analysis of the influence of antithrombin on microvascular thrombosis: anti-inflammation is crucial for anticoagulationMicrocirculatory alterations in ischemia-reperfusion injury and sepsis: effects of activated protein C and thrombin inhibition.Antithrombin is protective against myocardial ischemia and reperfusion injury.Pharmacology and clinical applications of human recombinant antithrombin.Recommendations for the use of antithrombin concentrates and prothrombin complex concentratesAntithrombin and hypercoagulability in sepsis: insights from thrombelastography?Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis.Antithrombin therapy in pancreas retransplantation and pancreas-after-kidney/pancreas-transplantation-alone patients.Antithrombin deficiency is associated with mortality and impaired organ function in septic pediatric patients: a retrospective study
P2860
Q24186159-31A2AB9B-5A13-43C3-8175-CA5D6AF53E2AQ24187024-AEC3CB72-99B6-4F43-8AB9-100C4CBD3251Q24242053-B9BB22F2-5010-45B2-BBDB-C783029655ECQ26751555-40DA2AE6-0A66-484A-A165-046B57F4EDFFQ33612689-9ED6EB2E-1F50-40BB-A85F-327D950DE117Q33753012-6BCFBDDA-92C2-42FE-8D8D-993E416854C8Q35107098-574DE8D8-6155-4858-8AAE-B6732FE1E0D0Q35629861-7CC6BACA-105D-4469-A389-7DDAD6EEC505Q35829030-35D32578-1695-4C5B-B9C6-F887E1785DAAQ36259598-44F7F495-5616-40B3-8C66-B7C28B2956F3Q36986076-7F3FC1D8-7DEB-4795-9FC9-857313A093FCQ37763191-169D8EDF-6DC4-47E0-B03D-4ABF9D6925DCQ42096335-7E4C9FA7-E112-4028-BBC2-7A9E5374011FQ42131380-2DE86A48-BA01-4481-8D0E-4EB7B917A217Q43182531-BD22F66D-B751-4D2F-AC23-905BDCFB0708Q44718059-1EE8F862-A229-4CF5-90B7-11735B134A6BQ58763094-5B6D9AB4-5784-4B60-9978-0B7037FE8A20
P2860
Effect of long-term and high-dose antithrombin supplementation on coagulation and fibrinolysis in patients with severe sepsis.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Effect of long-term and high-d ...... n patients with severe sepsis.
@en
Effect of long-term and high-d ...... n patients with severe sepsis.
@nl
type
label
Effect of long-term and high-d ...... n patients with severe sepsis.
@en
Effect of long-term and high-d ...... n patients with severe sepsis.
@nl
prefLabel
Effect of long-term and high-d ...... n patients with severe sepsis.
@en
Effect of long-term and high-d ...... n patients with severe sepsis.
@nl
P2093
P1476
Effect of long-term and high-d ...... n patients with severe sepsis.
@en
P2093
Dieter Mühlbayer
Dietrich Inthorn
Johannes N Hoffmann
Marianne Jochum
P304
P356
10.1097/01.CCM.0000139691.54108.1F
P407
P577
2004-09-01T00:00:00Z